L. Sadler et al., Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves, BR J OBST G, 107(2), 2000, pp. 245-253
Objectives Firstly, to compare pregnancy outcomes and cardiac complications
in women with: 1. either mechanical or bioprosthetic valves at the mitral
site; 2. mechanical valves treated with warfarin or subcutaneous heparin. S
econdly, to determine pregnancy and cardiac outcomes in women with aortic h
omograft valves.
Design Historical cohort study.
Setting Greenlane Hospital,Auckland, New Zealand.
Population Young women (n = 255) who had valve replacements between 1972 an
d 1992. Seventy-nine women underwent 147 pregnancies.
Main outcome measures Pregnancy loss, cardiac complications.
Results Pregnancy loss occurred in 59% of pregnancies with mitral mechanica
l valves (n = 50) and 7% with mitral bioprosthetic valves (n = 33) (RR 8.20
, 95% CI 2.10-31.93). Pregnancy loss rate was 70% in pregnancies treated wi
th warfarin, compared with 25% for those switched from warfarin to heparin
(RR 2.81, 95% CI 1.03-7.73). All heparin-associated losses occurred in the
first trimester, whereas there were four stillbirths with warfarin. Cardiac
complications occurred in 10 pregnancies (20%) in the women with mitral me
chanical valves and four (13%) with mitral bioprosthetic valves (RR 1.55, 9
5% CI 0.53-4.52). All four thromboembolic complications with mechanical val
ves occurred in the 14 women treated with heparin throughout pregnancy. Str
uctural valve deterioration occurred in four pregnancies (10%) with mitral
bioprosthetic valves. No cardiac complications or known pregnancy losses oc
curred with aortic homograft valves (n = 41).
Conclusion The high pregnancy loss rate in women with mitral mechanical val
ves was associated with warfarin throughout pregnancy, whereas the thromboe
mbolic cardiac complications were associated with heparin. Pregnancy outcom
e was very good in women with bioprosthetic and homograft valves.